Use of Artificial Intelligence-Guided Echocardiography to assIst cardiovascuLar Patient managEment

NCT05558605 · tracked via the Priya Life Science Australia tracker

Sponsor

Baker Heart and Diabetes Institute

Phase

Not applicable

Started

2023-02-24

Last updated

2025-10-20

Condition(s) studied

Heart FailureValve Heart Disease

Investigational drug(s) / intervention(s)

AI-guided echoStandard echo

AI-guided echo: AI-guided echocardiography

Standard echo: Standard echocardiography

Study summary

Heart Failure and valvular heart disease are disproportionate problems in rural and remote Australia (RRA). Echocardiography is the best imaging investigation, and essential for management, but access to this essential test shows huge geographic variations, primarily because of dependence on expert acquisition. This trial seeks to demonstrate the effectiveness of artificial intelligence-based echocardiography for triage and management of patients with known or suspected heart disease in RRA.

Eligibility

Sex

ALL

Min age

45 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Age \>45 years * eligible for Medicare * exercise intolerance or cardiovascular (CV) risk factors Exclusion Criteria: * Known HF or HVD * situations where cardio-protection is already indicated (eg. known CAD) * comorbid conditions with life expectancy \<2 years * inability to provide written informed consent

Primary outcome measure(s)

Diagnosis of cardiac dysfunction or heart valve disease — 12 months
Number of Participants with Diagnosis of cardiac dysfunction or heart valve disease

Trial sites (1)

Facility	City	Region	Status
Alice Springs Hospital	Alice Springs	Northern Territory	Recruiting

More Baker Heart and Diabetes Institute trials in Australia

Exercise to Improve Neurovascular Function in Breast Cancer Survivors Starting soon

Echo Acquisition Despite Geographic Separation by Replication of Human Movements (EAGER) Starting soon

Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE) Recruiting

Risk-guided Disease managEment Plan to prevEnt CAD in Patients Treated With Previous Cancer Recruiting

Risk-guided Disease Management Plan to Prevent Heart Failure in Patients Treated With Previous Chemotherapy (REDEEM) Recruiting

Other trials for the same condition

Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade Patients Active, not recruiting

REDUCE LAP-HF TRIAL II Active, not recruiting

ASCEND CSP IDE Study Active, not recruiting

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin Recruiting

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05558605 on ClinicalTrials.gov ↗ ← All trials in Australia